<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03998332</url>
  </required_header>
  <id_info>
    <org_study_id>LCNEC_2018</org_study_id>
    <nct_id>NCT03998332</nct_id>
  </id_info>
  <brief_title>Overall Survival of Large Cell Neuroendocrine Lung Cancer Patients - a Retrospective Study</brief_title>
  <official_title>Overall Survival and Progression Free Survival of Patients With Large Cell Neuroendocrine Lung Cancer and Combined Large Cell Neuroendocrine Lung Cancer Treated in Clinical Stage I-IV</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jaroslaw B. Cwikla, MD, PhD, Professor UWM</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Warmia and Mazury</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a retrospective study. 132 patients with LCNEC and combined LCNEC were included to
      the analysis. Patients were treated with radical, palliative or symptomatic intension between
      2002-2018 in central and north-eastern centres in Poland. The group of patients consists of
      47 women (36%) and 85 men (64%). Ratio of women to men is 1:1,81. The observation period
      ranged from 0 to 192 months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a retrospective study. 132 patients with LCNEC and combined LCNEC were included to
      the analysis. Patients were treated with radical, palliative or symptomatic intension between
      2002-2018 in central and north-eastern centres in Poland. The group of patients consists of
      47 women (36%) and 85 men (64%). Ratio of women to men is 1:1,81. The observation period
      ranged from 0 to 192 months.

      For all patients included to the analysis, the clinical stage was estimated according to TNM
      Classification of Malignant Tumours - UICC from 2017. The degree of pathomorphic stage (pTNM)
      was assessed in 60 patients treated with intention to treat (ITT), which is 45% of the total
      population.

      The degree of clinical stage (cTNM) was assessed in 72 patients based on the imaging
      examinations (including PET, CT, MRI, bone scintigraphy, etc.) and fine needle aspiration
      biopsy (FNA) (including EBUS, with pathological confirmation of LCNEC, which is 55% of the
      total population.

      The clinical stage (cTNM) was used in case of patients disqualified from radical surgery due
      to: advanced disease, contraindications to surgery, no patient's consent for treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2002</start_date>
  <completion_date type="Actual">December 31, 2018</completion_date>
  <primary_completion_date type="Actual">December 31, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>PFS - Progression Free Survival</measure>
    <time_frame>16 years</time_frame>
    <description>the time from the start of treatment date to the date of first observation of documented local recurrence, metastases or disease progression. Patients without progression at the time of analysis will be censored.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>OS - Overall Survival</measure>
    <time_frame>16 years</time_frame>
    <description>is defined as the time from the histopathological confirmation to the date of death due to any cause or the date of last contact (censored observation) at the date of data cut-off.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Log-rank test</measure>
    <time_frame>16 years</time_frame>
    <description>assessment of differences in survival of patients between subgroups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cox proportional-hazards model</measure>
    <time_frame>16 years</time_frame>
    <description>multivariate analyses used for investigating the association between the survival time of patients and prognostic factors</description>
  </secondary_outcome>
  <enrollment type="Actual">132</enrollment>
  <condition>Survival Outcomes of Patients With Pulmonary LCNEC</condition>
  <eligibility>
    <study_pop>
      <textblock>
        132 patients with LCNEC and combined LCNEC were included to the analysis. Patients were
        treated with radical, palliative or symptomatic intension between 2002-2018 in central and
        north-eastern centres in Poland. The group of patients consists of 47 women (36%) and 85
        men (64%). Ratio of women to men is 1:1,81. The observation period ranged from 0 to 192
        months.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults ≥18 years old, male or female, with pathologically confirmed primary
             neuroendocrine lung cancer based on histopathological examination:

               1. LCNEC

               2. combined type LCNEC

          -  Patients with LCNEC, combined LCNEC without prior treatment independently from the
             clinical stage according to the 8th edition of TNM 2017

          -  Patients with generalized, unresectable of LCNEC, combined LCNEC before, during and
             after palliative treatment

          -  Patients with generalized, unresectable LCNEC, combined LCNEC treated only
             symptomatically

          -  Patients with locally advanced, unresectable LCNEC,combined LCNEC before, during and
             after radical treatment

          -  Patients with locally advanced, resectable LCNEC, combined LCNEC before, during and
             after treatment

        Exclusion Criteria:

          -  NA
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>86 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jarosław B Ćwikła, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Warmia and Mazury</affiliation>
  </overall_official>
  <results_reference>
    <citation>Rekhtman N. Neuroendocrine tumors of the lung: an update. Arch Pathol Lab Med. 2010 Nov;134(11):1628-38. doi: 10.1043/2009-0583-RAR.1. Review.</citation>
    <PMID>21043816</PMID>
  </results_reference>
  <results_reference>
    <citation>Travis WD. Advances in neuroendocrine lung tumors. Ann Oncol. 2010 Oct;21 Suppl 7:vii65-71. doi: 10.1093/annonc/mdq380. Review.</citation>
    <PMID>20943645</PMID>
  </results_reference>
  <results_reference>
    <citation>Gustafsson BI, Kidd M, Chan A, Malfertheiner MV, Modlin IM. Bronchopulmonary neuroendocrine tumors. Cancer. 2008 Jul 1;113(1):5-21. doi: 10.1002/cncr.23542. Review.</citation>
    <PMID>18473355</PMID>
  </results_reference>
  <results_reference>
    <citation>Detterbeck FC. Management of carcinoid tumors. Ann Thorac Surg. 2010 Mar;89(3):998-1005. doi: 10.1016/j.athoracsur.2009.07.097. Review.</citation>
    <PMID>20172187</PMID>
  </results_reference>
  <results_reference>
    <citation>Wolin EM. Challenges in the Diagnosis and Management of Well-Differentiated Neuroendocrine Tumors of the Lung (Typical and Atypical Carcinoid): Current Status and Future Considerations. Oncologist. 2015 Oct;20(10):1123-31. doi: 10.1634/theoncologist.2015-0198. Epub 2015 Aug 25. Review.</citation>
    <PMID>26306904</PMID>
  </results_reference>
  <results_reference>
    <citation>Chong CR, Wirth LJ, Nishino M, Chen AB, Sholl LM, Kulke MH, McNamee CJ, Jänne PA, Johnson BE. Chemotherapy for locally advanced and metastatic pulmonary carcinoid tumors. Lung Cancer. 2014 Nov;86(2):241-6. doi: 10.1016/j.lungcan.2014.08.012. Epub 2014 Aug 27.</citation>
    <PMID>25218177</PMID>
  </results_reference>
  <results_reference>
    <citation>Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, Caplin M, Delle Fave G, Kaltsas GA, Krenning EP, Moss SF, Nilsson O, Rindi G, Salazar R, Ruszniewski P, Sundin A. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 2008 Jan;9(1):61-72. doi: 10.1016/S1470-2045(07)70410-2. Review.</citation>
    <PMID>18177818</PMID>
  </results_reference>
  <results_reference>
    <citation>Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003 Feb 15;97(4):934-59.</citation>
    <PMID>12569593</PMID>
  </results_reference>
  <results_reference>
    <citation>Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, Evans DB. One hundred years after &quot;carcinoid&quot;: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008 Jun 20;26(18):3063-72. doi: 10.1200/JCO.2007.15.4377. Review.</citation>
    <PMID>18565894</PMID>
  </results_reference>
  <results_reference>
    <citation>Vinik AI, Woltering EA, Warner RR, Caplin M, O'Dorisio TM, Wiseman GA, Coppola D, Go VL; North American Neuroendocrine Tumor Society (NANETS). NANETS consensus guidelines for the diagnosis of neuroendocrine tumor. Pancreas. 2010 Aug;39(6):713-34. doi: 10.1097/MPA.0b013e3181ebaffd.</citation>
    <PMID>20664471</PMID>
  </results_reference>
  <results_reference>
    <citation>Öberg K, Hellman P, Ferolla P, Papotti M; ESMO Guidelines Working Group. Neuroendocrine bronchial and thymic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012 Oct;23 Suppl 7:vii120-3.</citation>
    <PMID>22997444</PMID>
  </results_reference>
  <results_reference>
    <citation>Caplin ME, Baudin E, Ferolla P, Filosso P, Garcia-Yuste M, Lim E, Oberg K, Pelosi G, Perren A, Rossi RE, Travis WD; ENETS consensus conference participants. Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. Ann Oncol. 2015 Aug;26(8):1604-20. doi: 10.1093/annonc/mdv041. Epub 2015 Feb 2. Review.</citation>
    <PMID>25646366</PMID>
  </results_reference>
  <results_reference>
    <citation>Fisseler-Eckhoff A, Demes M. Neuroendocrine tumors of the lung. Cancers (Basel). 2012 Jul 31;4(3):777-98. doi: 10.3390/cancers4030777.</citation>
    <PMID>24213466</PMID>
  </results_reference>
  <results_reference>
    <citation>Detterbeck FC. Clinical presentation and evaluation of neuroendocrine tumors of the lung. Thorac Surg Clin. 2014 Aug;24(3):267-76. doi: 10.1016/j.thorsurg.2014.04.002. Review.</citation>
    <PMID>25065927</PMID>
  </results_reference>
  <results_reference>
    <citation>Pieterman CR, Conemans EB, Dreijerink KM, de Laat JM, Timmers HT, Vriens MR, Valk GD. Thoracic and duodenopancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1: natural history and function of menin in tumorigenesis. Endocr Relat Cancer. 2014 May 6;21(3):R121-42. doi: 10.1530/ERC-13-0482. Print 2014 Jun. Review.</citation>
    <PMID>24389729</PMID>
  </results_reference>
  <results_reference>
    <citation>Aguayo SM, Miller YE, Waldron JA Jr, Bogin RM, Sunday ME, Staton GW Jr, Beam WR, King TE Jr. Brief report: idiopathic diffuse hyperplasia of pulmonary neuroendocrine cells and airways disease. N Engl J Med. 1992 Oct 29;327(18):1285-8.</citation>
    <PMID>1406819</PMID>
  </results_reference>
  <results_reference>
    <citation>Gosney JR. Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia as a precursor to pulmonary neuroendocrine tumors. Chest. 2004 May;125(5 Suppl):108S.</citation>
    <PMID>15136447</PMID>
  </results_reference>
  <results_reference>
    <citation>Koo CW, Baliff JP, Torigian DA, Litzky LA, Gefter WB, Akers SR. Spectrum of pulmonary neuroendocrine cell proliferation: diffuse idiopathic pulmonary neuroendocrine cell hyperplasia, tumorlet, and carcinoids. AJR Am J Roentgenol. 2010 Sep;195(3):661-8. doi: 10.2214/AJR.09.3811. Review.</citation>
    <PMID>20729444</PMID>
  </results_reference>
  <results_reference>
    <citation>Chong S, Lee KS, Chung MJ, Han J, Kwon OJ, Kim TS. Neuroendocrine tumors of the lung: clinical, pathologic, and imaging findings. Radiographics. 2006 Jan-Feb;26(1):41-57; discussion 57-8. Review.</citation>
    <PMID>16418242</PMID>
  </results_reference>
  <results_reference>
    <citation>Travis WD, Rush W, Flieder DB, Falk R, Fleming MV, Gal AA, Koss MN. Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. Am J Surg Pathol. 1998 Aug;22(8):934-44.</citation>
    <PMID>9706973</PMID>
  </results_reference>
  <results_reference>
    <citation>Igawa S, Watanabe R, Ito I, Murakami H, Takahashi T, Nakamura Y, Tsuya A, Kaira K, Naito T, Endo M, Yamamoto N, Kameya T. Comparison of chemotherapy for unresectable pulmonary high-grade non-small cell neuroendocrine carcinoma and small-cell lung cancer. Lung Cancer. 2010 Jun;68(3):438-45. doi: 10.1016/j.lungcan.2009.07.003. Epub 2009 Aug 21.</citation>
    <PMID>19699548</PMID>
  </results_reference>
  <results_reference>
    <citation>Watanabe R, Ito I, Kenmotsu H, Endo M, Yamamoto N, Ohde Y, Kondo H, Nakajima T, Kameya T. Large cell neuroendocrine carcinoma of the lung: is it possible to diagnose from biopsy specimens? Jpn J Clin Oncol. 2013 Mar;43(3):294-304. doi: 10.1093/jjco/hys221. Epub 2013 Feb 3.</citation>
    <PMID>23381206</PMID>
  </results_reference>
  <results_reference>
    <citation>Kujtan L, Muthukumar V, Kennedy KF, Davis JR, Masood A, Subramanian J. The Role of Systemic Therapy in the Management of Stage I Large Cell Neuroendocrine Carcinoma of the Lung. J Thorac Oncol. 2018 May;13(5):707-714. doi: 10.1016/j.jtho.2018.01.019. Epub 2018 Jan 31.</citation>
    <PMID>29391287</PMID>
  </results_reference>
  <results_reference>
    <citation>Hiroshima K, Mino-Kenudson M. Update on large cell neuroendocrine carcinoma. Transl Lung Cancer Res. 2017 Oct;6(5):530-539. doi: 10.21037/tlcr.2017.06.12. Review.</citation>
    <PMID>29114469</PMID>
  </results_reference>
  <results_reference>
    <citation>Yang G, Pan Z, Ma N, Qu L, Yuan T, Pang X, Yang X, Dong L, Liu S. Leptomeningeal metastasis of pulmonary large-cell neuroendocrine carcinoma: A case report and review of the literature. Oncol Lett. 2017 Oct;14(4):4282-4286. doi: 10.3892/ol.2017.6676. Epub 2017 Jul 26.</citation>
    <PMID>28943940</PMID>
  </results_reference>
  <results_reference>
    <citation>Ramirez RA, Chauhan A, Gimenez J, Thomas KEH, Kokodis I, Voros BA. Management of pulmonary neuroendocrine tumors. Rev Endocr Metab Disord. 2017 Dec;18(4):433-442. doi: 10.1007/s11154-017-9429-9. Review.</citation>
    <PMID>28868578</PMID>
  </results_reference>
  <results_reference>
    <citation>Tang H, Wang H, Xi S, He C, Chang Y, Wang Q, Wu Y. Perioperative chemotherapy with pemetrexed and cisplatin for pulmonary large-cell neuroendocrine carcinoma: a case report and literature review. Onco Targets Ther. 2018 May 7;11:2557-2563. doi: 10.2147/OTT.S160565. eCollection 2018.</citation>
    <PMID>29765234</PMID>
  </results_reference>
  <results_reference>
    <citation>Derks JL, van Suylen RJ, Thunnissen E, den Bakker MA, Groen HJ, Smit EF, Damhuis RA, van den Broek EC, Speel EM, Dingemans AC; PALGA group. Chemotherapy for pulmonary large cell neuroendocrine carcinomas: does the regimen matter? Eur Respir J. 2017 Jun 1;49(6). pii: 1601838. doi: 10.1183/13993003.01838-2016. Print 2017 Jun.</citation>
    <PMID>28572122</PMID>
  </results_reference>
  <results_reference>
    <citation>Prelaj A, Rebuzzi SE, Del Bene G, Giròn Berrìos JR, Emiliani A, De Filippis L, Prete AA, Pecorari S, Manna G, Ferrara C, Rossini D, Longo F. Evaluation of the efficacy of cisplatin-etoposide and the role of thoracic radiotherapy and prophylactic cranial irradiation in LCNEC. ERJ Open Res. 2017 Mar 29;3(1). pii: 00128-2016. doi: 10.1183/23120541.00128-2016. eCollection 2017 Jan.</citation>
    <PMID>28382303</PMID>
  </results_reference>
  <results_reference>
    <citation>Kim KW, Kim HK, Kim J, Shim YM, Ahn MJ, Choi YL. Outcomes of Curative-Intent Surgery and Adjuvant Treatment for Pulmonary Large Cell Neuroendocrine Carcinoma. World J Surg. 2017 Jul;41(7):1820-1827. doi: 10.1007/s00268-017-3908-8.</citation>
    <PMID>28204910</PMID>
  </results_reference>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>June 18, 2019</study_first_submitted>
  <study_first_submitted_qc>June 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 26, 2019</study_first_posted>
  <last_update_submitted>June 27, 2019</last_update_submitted>
  <last_update_submitted_qc>June 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Warmia and Mazury</investigator_affiliation>
    <investigator_full_name>Jaroslaw B. Cwikla, MD, PhD, Professor UWM</investigator_full_name>
    <investigator_title>Head of Department of Radiology</investigator_title>
  </responsible_party>
  <keyword>LCNEC-Large cell neuroendocrine carcinoma</keyword>
  <keyword>Lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

